Company intelligence / Profile preview

AlloVir

Waltham, Massachusetts, United Statesallovir.com ↗

Ownership: Private
Employees: ~6
Development stage: Phase 1

Overview

The company faced significant setbacks in December 2023 when it abandoned three late-stage trials of its lead asset, causing shares to plunge 64%[7]. Previously had positive Phase 2 proof-of-concept data for lead program Viralym-M published in Journal of Clinical Oncology[5].

Therapeutic areas: Infectious Diseases
Modalities: Allogeneic T-cell therapiesMulti-virus specific T cell (VST) therapies
Industry: Biotech

Drug pipeline

1 asset

TH103

Phase 1

Indications: Neovascular age-related macular degeneration (nAMD)

Partnerships

Baylor College of Medicine's Center for Cell and Gene Therapy

Beyond the preview

Go deeper on AlloVir.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AlloVir.

Explore the full profile